Theravance Finds a Good Match for its Phase III-Ready Nebulised COPD Therapy in Mylan

By Heather Cartwright

Pharma Deals Review: Vol 2015 Issue 2 (Table of Contents)

Published: 19 Feb-2015

DOI: 10.3833/pdr.v2015.i2.2092     ISSN: 1756-7874

Section: Licensing



In a deal worth upto US$265 M, Theravance Biopharma has secured Mylan as a partner for the development and commercialisation of TD-4208, its Phase III-ready long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease that was previously licensed to GlaxoSmithKline...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details